linvoseltamab-gcpt (Lynozyfic)

Indications

• treatment of adult patients with relapsed or refractory multiple myeloma who have received >= 4 prior lines of therapy, including
  • a proteasome inhibitor
  • an immunomodulatory agent
  • an anti-CD38 monoclonal antibody

Contraindications

• pregnancy

Dosage

• IV infusion

5 mg/2.5 mL (2 mg/mL) single-dose vial

200 mg/10 mL (20 mg/mL) single-dose vial

Monitor

• CBC, LFTs baseline & periodically during treatment

Adverse effects

• >= 20%
  • musculoskeletal pain, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, dyspnea
  • cytokine release syndrome
• anemia, neutropenia, lymphopenia
• hepatotoxicity
• immune effector cell-associated neurotoxicity syndrome (ICANS)

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager

Notes

• available only through a restricted program called the LYNOZYFIC Risk Evaluation & Mitigation Strategy (REMS).

More general terms

• antineoplastic monoclonal antibody